Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2593_Библиотеки_им_академика_М_И_Перельмана
.pdf
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
receiving palliative care. Cochrane Database Syst Rev.
2018;6(6):CD006332.
Barnett V, Twycross R, Mihalyo M, Wilcock A. Opioid antagonists. J Pain
Symptom Manage. 2014;47:341–352.
RedBook Online [database online]. IBM Micromedex. Updated periodically.
Accessed November 20, 2020. https://www.ibm.com/products/micromedexred-book
Kutner JS, Blatchford PJ, Taylor DH Jr. Safety and benefit of discontinuing
statin therapy in the setting of advanced, life-limiting illness: a randomized
clinical trial. JAMA Intern Med. 2015;175(5):691–700.
Taylor JK, Pendleton N. Progesterone therapy for the treatment of noncancer cachexia: a systematic review. BMJ Support Palliat Care.
2016;6:276–286.
Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL,
Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia
syndrome. Cochrane Database Syst Rev. 2013;2013(3):CD004310.
Megesterol acetate oral. Facts and Comparisons®. Updated November 3,
2020. Accessed November 20, 2020.
https://fco.factsandcomparisons.com/lco/action/home
Buckley JS, Salpeter SR. A risk-benefit assessment of dementia
medications: systematic review of the evidence. Drugs Aging. 2015;32:453–
467.
Zueger PM, Holmes HM, Calip GS, Qato DM, Pickard AS, Lee TA. Older
Medicare beneficiaries frequently continue medications with limited benefit
following hospice admission. J Gen Intern Med. 2019;34(10):2029–2037.
Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of
medications of questionable benefit in advanced dementia. JAMA Intern
Med. 2014;174(11):1763–1771.
Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and
vomiting in palliative care patients. Cochrane Database Syst Rev.
2015;2015(11):CD006271.
Saudemont G, Prod’Homme C, Da Silva A, et al. The use of olanzapine as
an antiemetic in palliative medicine: a systematic review of the literature.
BMC Palliat Care. 2020;19(1):56.
The Center to Advance Palliative Care. Icahn School of Medicine at Mount
Sinai. Accessed November 22, 2020. https://www.capc.org/
Bishop MF, Stephens L, Goodrich M, Byock I. Medication kits for managing
symptomatic emergencies in the home: a survey of common hospice
practice. J Palliat Med. 2009;12(1):37–44.
Leigh AE, Burgio KL, Williams BR, Kvale E, Bailey FA. Hospice emergency
kit for veterans: a pilot study. J Palliat Med. 2013;16(4):356–361.
Institute of Medicine. Dying in America: Improving Quality and Honoring
Individual Preferences Near the End of Life. The National Academies Press;
https://t.me/medicina_free
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
2015.
Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL,
et al, eds. Goodman & Gilman’s: The Pharmacological Basis of
Therapeutics. 11th ed. McGraw-Hill; 2006:547.
Parshall MB, Schwartzstein RM, Adams L, et al. An official American
Thoracic Society statement: update on the mechanisms, assessment, and
management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452.
Mularski RA, Reinke LF, Carrieri-Kohlman V, et al. An official American
Thoracic Society workshop report: assessment and palliative management of
dyspnea crisis. Ann Am Thorac Soc. 2013;10(5):S98–S106.
Mercadante S. Episodic breathlessness in patients with advanced cancer:
characteristics and management. Drugs. 2018;78:543–547.
Hallenbeck J. Pathophysiologies of dyspnea explained: why might opioids
relieve dyspnea and not hasten death? J Palliat Med. 2012;15(8):848–853.
Lok CW. Management of breathlessness in patients with advanced cancer: a
narrative review. Am J Hosp Palliat Care. 2016;33(3):286–290.
Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of
refractory breathlessness in adults with advanced disease and terminal
illness. Cochrane Database Syst Rev. 2016;3(3):CD011008.
Afolabi TM, Nahata MC, Pai V. Nebulized opioids for the palliation of
dyspnea in terminally ill patients. Am J Health Syst Pharm.
2017;74(14):1053–1061.
Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the
treatment of cancer pain: evidence-based recommendations from the EAPC.
Lancet Oncol. 2012;13(2):e58–e68.
Simon ST, Higginson IJ, Booth S, Harding R, Weingärtner V, Bausewein C.
Benzodiazepines for the relief of breathlessness in advanced malignant and
non-malignant diseases in adults. Cochrane Database Syst Rev.
2016;10(10):CD007354.
Horsfall JT, Sprague JE. The pharmacology and toxicology of the ‘Holy
Trinity’. Basic Clin Pharmacol Toxicol. 2017;120(2):115–119.
Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of
prescription opioids and benzodiazepines and overdose: retrospective
analysis. BMJ. 2017;356:j760.
Henson LA, Maddocks M, Evans C, Davidson M, Hicks S, Higginson IJ.
Palliative care and the management of common distressing symptoms in
advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue. J
Clin Oncol. 2020;38(9):905–914.
Albert RH. End-of-life care: managing common symptoms. Am Fam
Physician. 2017;95(6):356–361.
Lokker ME, van Zuylen L, van der Rijt CC, van der Heide A. Prevalence,
impact, and treatment of death rattle: a systematic review. J Pain Symptom
Manage. 2014;47(1):105–122.
https://t.me/medicina_free
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
Mercadante S. Death rattle: critical review and research agenda. Support
Care Cancer. 2014;22:571–575.
van Esch HJ, Lokker ME, Rietjens J, van Zuylen L, van der Rijt CCD, van der
Heide A. Understanding relatives’ experience of death rattle. BMC Psychol.
2020;8(1):62–71.
Campbell ML. Assuaging listener distress from patient death rattle. Ann
Palliat Med. 2019;8(suppl 1):S58–S60.
Jansen K, Haugen DF, Pont L, Ruths S. Safety and effectiveness of palliative
drug treatment in the last days of life—a systematic literature review. J Pain
Symptom Manage. 2018;55(2):508–521.
Wee B, Hillier R. Interventions for noisy breathing in patients near to death.
Cochrane Database Syst Rev. 2008;(1):CD005177.
Mercadante S, Marinangeli F, Masedu F, et al. Hyoscine butylbromide for the
management of death rattle: sooner rather than later. J Pain Symptom
Manage. 2018;56(6):902–907.
Transderm Scop (scopolamine). Prescribing information. Perrigo New York
Inc. Accessed November 30, 2020.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e374a27-92f6-f21703ae7bdf
Edwards H, Bennett M. Access to opioids for patients with advanced
disease. Curr Pharm Des. 2019;25(30):3203–3208.
Paice JA. Cancer pain management and the opioid crisis in America: how to
preserve hard-earned gains in improving the quality of cancer pain
management. Cancer. 2018;124(12):2491–2497.
Brown JH, Torres HP, Maddi RD, et al. Cancer patients’ perceived difficulties
filling opioid prescriptions after receiving outpatient supportive care. J Pain
Symptom Manage. 2020;60(5):915–922.
Jefferson K, Quest T, Yeager KA. Factors associated with black cancer
patients’ ability to obtain their opioid prescriptions at the pharmacy. J Palliat
Med. 2019;22(9):1143–1148
Twillman RK, Gilson AM, Duensing KN. State policies regulating the practice
of pain management: statutes, rules, and guidelines that shape pain care.
Anesthesiol Clin. 2016;34(2):409–424.
Bonnie RJ, Schumacher MA, Clark JD, Kesselheim AS. Pain management
and opioid regulation: continuing public health challenges. Am J Public
Health. 2019;109(1):31–34.
National Academies of Sciences, Engineering, and Medicine. Pain
Management and the Opioid Epidemic: Balancing Societal and Individual
Benefits and Risks of Prescription Opioid Use. The National Academies
Press; 2017.
U.S. Food and Drug Administration. Code of Federal Regulations. Title 21.
21 CFR 1306. Accessed November 30, 2020. https://www.ecfr.gov/cgibin/text-idx?
https://t.me/medicina_free
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
SID=40855a45033124df0ceeb2446776b800&mc=true&node=pt21.9.1306&r
gn=div5
Electronic Prescriptions for Controlled Substances. Drug enforcement
administration. Accessed October 30, 2020.
https://www.deadiversion.usdoj.gov/ecomm/e_rx/
American Pharmacists Association. Controlled substance e-prescribing now
legal in all 50 states. Accessed October 30, 2020.
https://www.pharmacist.com/article/controlled-substance-e-prescribing-nowlegal-all-50states#:~:text=Electronic%20prescribing%20of%20controlled%20substances
,but%20does%20not%20require%20it
CONGRESS.GOV. H.R. 6—SUPPORT for Patients and Communities Act.
Accessed October 30, 2020. https://www.congress.gov/bill/115thcongress/house-bill/6
Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological
treatment of neuropathic cancer pain: a comprehensive review of the current
literature. Pain Pract. 2012;12:219–251.
Piano V, Verhagen S, Schalkwijk A, et al. Treatment for neuropathic pain in
patients with cancer: comparative analysis of recommendations in national
clinical practice guidelines from European countries. Pain Pract. 2014;1:1–7.
Mennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S.
Prevalence and aetiology of neuropathic pain in cancer patients: a
systematic review. Pain. 2012;153:359–365.
Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis
Primers. 2017;3:17002–17047.
Schumacher MA, Basbaum AI, Naidu RK. Opioid agonists & antagonists. In:
Katzung BG, ed. Basic & Clinical Pharmacology. 14th ed. McGraw-Hill;
Accessed December 2, 2020. https://accessmedicine-mhmedicalcom.ucsf.idm.oclc.org/content.aspx?bookid=2249§ionid=175220393
Aggarwal S, Mortensen OV. Overview of monoamine transporters. Curr
Protoc Pharmacol. 2017;79:12.16.1–12.16.17.
Hanna V, Senderovich H. Methadone in pain management: a systematic
review. J Pain. 2021;22(3):233–245.
McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in
adults. Cochrane Database Syst Rev. 2017;5(5):CD012499.
Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain.
Cochrane Database Syst Rev. 2017;2(2):CD003971.
McPherson ML, Walker KA, Davis MP, et al. Safe and appropriate use of
methadone in hospice and palliative care: expert consensus white paper. J
Pain Symptom Manage. 2019;57(3):635–645.
Methadone hydrochloride (methadone hydrochloride tablets). Prescribing
information. Glenmark Pharmaceuticals. Revised November 2019. Accessed
https://t.me/medicina_free
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
December 1, 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=4f732f01-0529-4aa6-b6a9-67fb7817a138
Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice
guideline from the American Pain Society and College on Problems of Drug
Dependence, in collaboration with the Heart Rhythm Society. J Pain.
2014;15:321–337.
Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A
Scientific Statement From the American Heart Association. Circulation.
2020;142(15):e214-e233.
Duragesic (fentanyl transdermal system). Highlights of prescribing
information. Janssen Pharmaceuticals, Inc. Updated September 2018.
Accessed December 3, 2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019813s075s07
6lbl.pdf
McPherson ML. Transdermal and parenteral fentanyl. In: Demystifying
Opioid Conversion Calculations: A Guide for Effective Dosing. 2nd ed.
American Society of Health-System Pharmacists. 2018:83–106.
U.S. Department of Justice, Drug Enforcement Administration. Diversion
control division. Accessed November 21, 2020.
https://www.deadiversion.usdoj.gov/drug_disposal/index.html
Emanuel EJ, Onwuteaka-Philipsen BD, Urwin JW, Cohen J. Attitudes and
practices of euthanasia and physician-assisted suicide in the United States,
Canada, and Europe. JAMA. 2016;316(1):79–90.
Quill TE, Back AL, Block SD. Responding to patients requesting physicianassisted death: physician involvement at the very end of life. JAMA.
2016;315(3):245–246.
Yang YT, Curlin FA. Why physicians should oppose assisted suicide. JAMA.
2016;315(3):247–248.
Goslin LO, Roberts AE. Physician-assisted dying: a turning point? JAMA.
2016;315(3):249–260.
Nyugen HQ, Gelman EJ, Bush TA, Lee JS, Kanter MH. Characterizing
Kaiser Permanente Southern California’s experience with the California End
of Life Option Act in the first year of implementation. Research letter. JAMA
Intern Med. 2018;178(3):417–421.
Hetzler PT 3rd, Nie J, Zhou A, Dugdale LS. A report of physicians’ beliefs
about physician-assisted suicide: a national study. Yale J Biol Med.
2019;92(4):575–585.
Campbell CS. Mortal responsibilities: bioethics and medical-assisted dying.
Yale J Biol Med. 2019;92(4):733–739.
Dugdale LS, Lerner BH, Callahan D. Pros and cons of physician aid in dying.
Yale J Biol Med. 2019;92(4):747–750.
Sulmasy LS, Mueller PS. Ethics and the legalization of physician-assisted
suicide: an American College of Physicians position paper. Ann Intern Med.
https://t.me/medicina_free
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
2017;167:576–578.
Oakman BN, Campbell HE, Runk LM. Death with dignity; the developing
debate among health care professionals. Consult Pharm. 2015;30:352–355.
Fass J, Fass A. Physician-assisted suicide: ongoing challenges for
pharmacists. Am J Health Syst Pharm. 2011;68:846–849.
Quill TE, Arnold RM, Youngner SJ. Physician-assisted suicide: finding a path
forward in a changing legal environment. Ann Intern Med. 2017;167(8):597–
598.
Kussmaul WG 3rd. The slippery slope of legalization of physician-assisted
suicide. Ann Intern Med. 2017;167(8):595–596.
Fujioka JK, Mirza RM, McDonald PL, Klinger CA. Implementation of medical
assistance in dying: a scoping review of health care providers’ perspectives.
J Pain Symptom Manage. 2018;55(6):1564–1576.
Cobaugh DJ. Medical aid in dying. Am J Health Syst Pharm.
2017;74(16):1214–1215.
Hughes MT. The pharmacist and medical aid in dying. Am J Health Syst
Pharm. 2017;74(16):1253–1260.
The American Society of Health-System Pharmacy. Policy position on
medical aid-in-dying. Accessed January 9, 2021.
https://www.ashp.org/-/media/assets/policy-guidelines/docs/policypositions/policy-positions-ethics.ashx
Woods P, Schindel TJ, King MA, Mey A. Pharmacy practice in the domain of
assisted dying: a mapping review of the literature. Res Social Adm Pharm.
2020;16(3):267–276.
National Hospice and Palliative Care Organization. Resource list: NHPCO
LAD resource series. Accessed January 8, 2021. https://www.nhpco.org/wpcontent/uploads/LAD_resource_List.pdf
National Hospice and Palliative Care Organization. State information and
links: NHPCO LAD resource series. Accessed January 8, 2021.
https://www.nhpco.org/wp-content/uploads/LAD_state_information.pdf
The American Academy of Hospice and Palliative Medicine. Statement on
palliative sedation. Accessed January 10, 2021.
http://aahpm.org/positions/palliativesedation#:~:text=Palliative%20sedation%20(PS)%2C%20as,with%20severe
%20and%20refractory%20symptoms
Kirk TW, Mahon MM, Palliative Sedation Task Force of the National Hospice
and Palliative Care Organization Ethics Committee. National Hospice and
Palliative Care Organization (NHPCO) position statement and commentary
on the use of palliative sedation in imminently dying terminally ill patients. J
Pain Symptom Manage. 2010;39:914–923.
Gurschick L, Mayer DK, Hanson LC. Palliative sedation: an analysis of
international guidelines and position statements. Am J Hosp Palliat Care.
2015;32(6):660–671.
https://t.me/medicina_free
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
Ciancio AL, Mirza RM, Ciancio AA, Klinger CA. The use of palliative sedation
to treat existential suffering: a scoping review on practices, ethical
considerations, and guidelines. J Palliat Care. 2020;35(1):13–20.
Beller EM, van Driel ML, McGregor L, Truong S, Mitchell G. Palliative
pharmacological sedation for terminally ill adults. Cochrane Database Syst
Rev. 2015;1(1):CD010206.
Kon AA. Palliative sedation: it’s not a panacea. Am J Bioeth. 2011;11(6):41–
42.
Meilaender G. Comforting when we cannot heal: the ethics of palliative
sedation. Theor Med Bioeth. 2018;39(3):211–220.
Curlin FA. Palliative sedation: clinical context and ethical questions. Theor
Med Bioeth. 2018;39(3):197–209.
Raus K, Sterckx S, Mortier F. Is continuous sedation at the end of life an
ethically preferable alternative to physician-assisted suicide? Am J Bioeth.
2011;11(6):32–40.
Bodnar J. A review of agents for palliative sedation/continuous deep
sedation: pharmacology and practical applications. J Pain Palliat Care
Pharmacother. 2017;31(1):16–37.
Ghafoor VL, Silus LS. Developing policy, standard orders, and qualityassurance monitoring for palliative sedation therapy. Am J Health Syst
Pharm. 2011;68:523–527.
Lam YWF, Lam A, Macy B. Pharmacokinetics of phenobarbital in
microenema via Macy Catheter versus suppository. J Pain Symptom
Manage. 2016;51(6):994–1001.
Afsharimani B, Kindl K, Good P, Hardy J. Pharmacological options for the
management of refractory cancer pain—what is the evidence? Support Care
Cancer. 2015;23:1473–1481.
Mercadante S. Managing difficult pain conditions in the cancer patient. Curr
Pain Headache Rep. 2014;18:395–401.
Vissers KC, Besse K, Wagemans M, et al. Pain in patients with cancer. Pain
Pract. 2011;11:453–475.
Brant JM, Keller L, McLeod K, Yeh C, Eaton LH. Chronic and refractory pain:
a systematic review of pharmacologic management in oncology. Clin J Oncol
Nurs. 2017;21(suppl 3):31–53.
Lee JT, Sanderson CR, Xuan W, Agar M. Lidocaine for cancer pain in adults:
a systematic review and meta-analysis. J Palliat Med. 2019;22(3):326–334.
Seah DSE, Herschtal A, Tran H, et al. Subcutaneous lidocaine infusion for
pain in patients with cancer. J Palliat Med. 2017;20:667–671.
Peixoto RD, Hawley P. Intravenous lidocaine for cancer pain without
electrocardiographic monitoring: a retrospective review. J Palliat Med.
2015;18:373–377.
Kintzel PE, Knol JD, Roe G. Intravenous lidocaine administered as twice
daily bolus and continuous infusion for intractable cancer pain and wound
https://t.me/medicina_free
care pain. J Palliat Med. 2019;22(3):343–347.
https://t.me/medicina_free
1
2
7
Interprofessional Practice and
Education
Michael G. Carvalho, Edith Claros, Christopher K. Cooper, and
Kaelen C. Dunican
CORE PRINCIPLES
CHAPTER CASES
The Interprofessional Practice and
Education Collaborative (IPEC)
produced an original report with a 2016
update developed by an expert panel
that established four core competencies
of interprofessional practice and
education (IPE): (a) values and ethics
for interprofessional practice; (b) roles
and responsibilities; (c) interprofessional
communication; and (d) teams and
teamwork.
Case 7-1 (Question 1)
Case 7-3 (Questions
1–5)
The IPEC report considers
communication a key competency.
Unfortunately, this can be negatively
Case 7-2 (Question 1)
https://t.me/medicina_free
3
4
5
impacted by demographic and
professional differences that may exist
between health care professionals. To
address this issue, the IPEC report
encourages all team members to be
willing to speak up in a respectful way if
they have a patient-related concern.
Although one should understand what
IPE is, it is also important to clarify what
does not constitute IPE. Experiences on
Advanced Pharmacy Practice
Experience (APPE) rotations that are
directed by someone from another
profession that do not include sharing of
responsibility for patient care are not
considered IPE.
Case 7-4 (Question 1)
One element of an IPE model is
understanding that different professions
may vary in how they approach patient
care. Team-based care means a shared
responsibility for patient care on the part
of all team members and should not be
dominated by any one profession. IPE
models can take place in a variety of
settings, such as a classroom,
laboratory, and a patient care setting.
Regardless of the environment, IPErelated activities should represent a
“real-world” experience.
Case 7-5 (Question 1)
Incorporating IPE in the pharmacy
curriculum should involve early
exposure to enhance students’
confidence in their professional value,
Case 7-6 (Question 1)
Case 7-7 (Questions
1, 2)
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана